Prevents angina pectoris due to coronary artery disease. ANDA 210822, held by Dexcel Ltd. Isosorbide Mononitrate.
As of Nov 16, 2026, ANDA 210822 (Isosorbide Mononitrate), held by Dexcel Ltd, was first approved by FDA on Aug 29, 2018, with 1 approved supplement and 0 published complete response letters.
INDICATIONS & USAGE Isosorbide mononitrate extended-release tablets are indicated for the prevention of angina pectoris due to coronary artery disease. The onset of action of oral isosorbide mononitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 29, 2018 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Isosorbide Mononitrate120MG · tablet, extended release;oral | Isosorbide Mononitrate | Rx |
| Jul 14, 2025 | Supplement 4Labeling · Standard review | Approved | None posted |
| Aug 29, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters